{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Back Bay Life Science Report","title":"Monthly Roundup of News from Healthcare Development","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/8b0e7742\"></iframe>","width":"100%","height":180,"duration":1804,"description":"In our latest podcast, Back Bay Life Science Advisors focused on the chronic and rare disease development of kidney disease. Recently, there have been some changes in treatment, some recent commercial launches and certainly some interest from pharma consolidators, as M&A activity picks up in this area.\n \nIn this next installment of The Life Science Report, Dr. Pete Bak and Christian Thienel of Back Bay Life Science Advisors talk about kidney disease and the various aspects of the renal disease landscape.\n \nTopics in this podcast include:\nThe links between cardio and metabolic diseases and the therapeutic approaches and label expansions taking place in the renal disease landscape\nHistoric evolutions beyond Chronic Kidney Disease (CKD), from rare diseases to all types of indications of CKD\nUnderstanding potential treatment priorities when some therapies have benefits in multiple indications\nRecent deals, including Novartis’ acquisition of Chinook Therapeutics and Novo Nordisk’s acquisition of KBP Biosciences’ ocedurenone, etc. \nThe impact of Sodium-glucose cotransporter-2s (SGLT2s) in kidney disease over the last ~5 years, and how that has precipitated broader interest in renal indications across the industry","thumbnail_url":"https://img.transistorcdn.com/W6Lngt-BhnFN8FVt3HSPeq-NUJHgo4jaJncMb2aU6_E/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS81NjE3/MTc3NDg3NzgyNTI0/ODE3Y2ViM2Q4OWI5/MDUzMC5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}